Week 158: Hanging out in Heidelberg

Written by Lars Haakon Soraas
02
Sep

Week 158 in the war on lung cancer has passed. Here are highlights:

  • The results from the brain MRI have come back. They were, unfortunately, a bit unclear. They have used a new machine to do the scan and this makes comparison to earlier scans a bit tricky. They wonder if they may see something going on. But very uncertain. Nothing much to do about it other than wait and see how things look at the next scan.
  • It seems doing a biopsy from one of the three growing metastasis in the lungs is more tricky than anticipated. So the local hospital here may not be able to do it anyway. And as the local hospital here are not able to do a so-called liquid biopsy (a sophisticated blood test where they look for cancer mutations), it may be that we will not know anytime soon what is driving progression in the lung. This is less than ideal.
  • We are looking into various options when it comes to dealing with the three growing lesions in the lungs. We are considering stereotactic radiation, ablation and changes in systemic therapy. One option we consider is a combination of osimertinib (a drug Dyanne is already on) and two other drugs: cetuximab and trastuzumab. The rationale for this combination is provided in this article by Prof Yarden and co. Another option we consider is an oncolytic virus.
  • We were in Germany this past week and Dyanne got another vaccine injection and also low dose nivolumab. On previous occasions she has gotten some stomach issues following the nivolumab. Now, after she has gotten the fecal transplant, it seems the stomach issues have stayed away. Whether it is a coincidence or is due to the fecal transplant, we don’t know.

While in Germany we met another young EGFR mutant lung cancer patients. She was 27 when diagnosed and we had a great time hanging out with her in Heidelberg.

Hope everyone has had a good weekend!

Dyanne and Lars on an old bridge in Heidelberg

Follow this blog

Get every new post delivered right to your inbox.